New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareHexarelin vs Chonluten

Hexarelin vs Chonluten

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
Hexarelin
Anti-Aging & Longevity
Chonluten
Summary
Hexarelin is a potent synthetic GHRP and the strongest GH secretagogue in its class per unit dose. It also exhibits unique cardioprotective properties through direct binding to cardiac CD36 receptors, independent of GH release. Its potency is balanced by a tendency to desensitize GH release with prolonged use, making cycling important.
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Half-Life
~70 minutes
Short (minutes for the peptide); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
100–200 mcg
10 mg per day
Frequency
2–3 times daily
Daily for 10–30 days
Key Benefits
  • Strongest GH pulse per mcg among GHRPs
  • Unique direct cardioprotective effects via CD36
  • Increased IGF-1 and muscle anabolism
  • Accelerated recovery from training
  • Bone density support
  • Anti-aging via GH axis
  • Potential cardiac rehabilitation benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
Side Effects
  • Water retention
  • Elevated cortisol
  • Elevated prolactin (more pronounced than other GHRPs)
  • Receptor desensitization with continuous use
  • +1 more
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
Stacks With